Pharmacovigilance Process in India: An overview

Prashant N. Amale, S. Deshpande, Nakhate Yd, Arsod Na
{"title":"Pharmacovigilance Process in India: An overview","authors":"Prashant N. Amale, S. Deshpande, Nakhate Yd, Arsod Na","doi":"10.4172/2329-6887.1000259","DOIUrl":null,"url":null,"abstract":"Clinical trial study of drug generally detects common Adverse Drug Reaction (ADR) but, the reaction which occurs after long duration in a specific person or population remains undetected. Pharmacovigilance (PV) is a scientific activity which keeps constant watch on the drug throughout its life cycle. In India, Indian Pharmacopoeia Commission (IPC) and National Coordination Committee (NCC) through the Central Drug Standard Control Organization (CDSCO) cordially regulate the PV activity. To build a potential PV system in India, Pharmacovilance Program of India (PvPI) have been proposed and implemented by the Indian government in 2010. The accurate detection and reporting of ADR is a heart of this system. Hence various regional, zonal and peripheral centres have been proposed for the smooth and effective reporting of ADR. Anyone can report ADR by filling the suspect ADR reporting form available online or offline to the nearest centre in suitable language. Considering Indian geographical distribution, huge population and mobile network connectivity, a toll free number and the mobile app is also provided for timely and effective reporting of ADR. The reported ADRs are collected and processed at the centres in Vigi-flow software. These centres detect signal which are reported to CDSCO and World Health Organisation (WHO) for the further regulatory action. CDSCO-WHO communicates their decision through a suitable media for the betterment of public health.","PeriodicalId":16958,"journal":{"name":"Journal of Pharmacovigilance","volume":"28 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacovigilance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6887.1000259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Clinical trial study of drug generally detects common Adverse Drug Reaction (ADR) but, the reaction which occurs after long duration in a specific person or population remains undetected. Pharmacovigilance (PV) is a scientific activity which keeps constant watch on the drug throughout its life cycle. In India, Indian Pharmacopoeia Commission (IPC) and National Coordination Committee (NCC) through the Central Drug Standard Control Organization (CDSCO) cordially regulate the PV activity. To build a potential PV system in India, Pharmacovilance Program of India (PvPI) have been proposed and implemented by the Indian government in 2010. The accurate detection and reporting of ADR is a heart of this system. Hence various regional, zonal and peripheral centres have been proposed for the smooth and effective reporting of ADR. Anyone can report ADR by filling the suspect ADR reporting form available online or offline to the nearest centre in suitable language. Considering Indian geographical distribution, huge population and mobile network connectivity, a toll free number and the mobile app is also provided for timely and effective reporting of ADR. The reported ADRs are collected and processed at the centres in Vigi-flow software. These centres detect signal which are reported to CDSCO and World Health Organisation (WHO) for the further regulatory action. CDSCO-WHO communicates their decision through a suitable media for the betterment of public health.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度的药物警戒过程:综述
药物的临床试验研究一般能检测到常见的药物不良反应(ADR),但在特定的人或人群中持续较长时间后发生的反应却无法检测到。药物警戒(PV)是一项对药物整个生命周期进行持续监测的科学活动。在印度,印度药典委员会(IPC)和国家协调委员会(NCC)通过中央药物标准控制组织(CDSCO)对PV活性进行规范。为了在印度建立一个有潜力的光伏系统,印度政府于2010年提出并实施了印度药物警戒计划(PvPI)。准确发现和报告不良反应是该系统的核心。因此,已经提出了各种区域、区域和外围中心,以便顺利和有效地报告不良反应。任何人都可以通过在线或离线填写可疑ADR报告表格,以适当的语言向最近的中心报告ADR。考虑到印度的地理分布、庞大的人口和移动网络连接,还提供了免费电话和移动应用程序,以便及时有效地报告ADR。报告的adr在各中心用Vigi-flow软件收集和处理。这些中心检测信号,并向CDSCO和世界卫生组织(WHO)报告,以便采取进一步的监管行动。疾控组织-世卫组织通过适当的媒体宣传其决定,以改善公众健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Drug Safety Monitoring in Health Programs of Cameroon. A Concise Outline on Measure behind Inoculation A Note on Medical Management of Uveitis Comparison of Traditional Medicine and Modern Medicine from Natural Products A Note on Protocol Writing In Clinical Research
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1